

# Vaccines and Global Health: The Week in Review 28 September 2024 :: Issue 768 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks


# Milestones, Perspectives

:::::::

#### **UN – Summit of the Future**

New York, September 2024

As an outcome of the Summit, world leaders adopted a Pact for the Future that includes a Global Digital Compact and a Declaration on Future Generations (<u>A/RES/79/1</u>). The Pact covers a broad range of themes including peace and security, sustainable development, climate change, digital cooperation, human rights, gender, youth and future generations, and the transformation of global governance.



# Pact for the Future, Global Digital Compact and Declaration on Future Genrationse

Summit of the Future – Outcome Documents
United Nations September 2024 :: 66 pages

PDF: https://www.un.org/sites/un2.un.org/files/sotf-the-pact-for-the-future.pdf

[vaccines/immunization references]

#### Pact for the Future

...Action 34. We will invest in the social and economic development of children and young people so that they can reach their full potential.

**...60**. We stress the importance of investing in, and ensuring equitable access to, essential services for all children and young people, especially health, education and social protection, to advance their social and economic development. To fulfil their full potential and secure decent, productive work and quality employment, young people must have access to safe, inclusive, equitable and quality education opportunities, including in emergencies, throughout their lives that equip them with the knowledge, skills and capabilities they need to thrive in a rapidly changing world. We decide to:

...(b) Accelerate efforts to achieve universal health coverage to ensure that all young people enjoy the highest attainable standard of physical and mental health, including

**immunizations and vaccinations** and sexual and reproductive health, and address all the challenges faced by developing countries in achieving these goals;

#### Annex II

#### **Declaration on Future Generations**

#### ...Commitments

...23. Protect the right to the enjoyment of the highest attainable standard of physical and mental health, through universal health coverage and strengthened and resilient health systems, as well as equitable access to safe, affordable, effective and quality medicines, vaccines, therapeutics and other health products, to ensure healthy lives and promote well -being for present and future generations...

# ::::::

#### Mpox - PHEIC

# Mpox - Multi-country external situation report n. 37, published 22 September 2024

KEY FIGURES							
Reporting period: 01 Ja	nuary 2022 – 31 Aug	just 2024					
Area	Number of reported confirmed cases		Number of deaths among confirmed cases		Number countries reporting cases		
Global	106 310		234		123		
Reporting period: 01 Ja	nuary 2024 – 15 Sep	tember 20	24				
Area	Number of reported confirmed cases	Numl deaths confirme		Number of reported suspected ca		Number of deaths among suspected cases	
Africa	6201	32		29 342		812	
Democratic Republic of the Congo¹	5399	2	5	25 757		806	
Burundi <sup>2</sup>	564	0	)	1557		0	

#### **Highlights**

- This situation report provides an update of the weekly mpox epidemiological situation in Africa, and the monthly global epidemiological situation.
- While the global outbreak linked to clade II MPXV is ongoing in most affected countries outside of Africa, outbreaks of clade I MPXV continue to occur in areas known to be endemic for mpox and cases linked to clade Ib MPXV continue to be reported in the eastern provinces of the Democratic Republic of the Congo and in an expanding outbreak in Burundi.
- Stockouts of tests in recent weeks hinder the confirmation of mpox cases in the Democratic Republic of the Congo.
- As of the end of August 2024, 2082 confirmed mpox cases were reported globally, marking the highest number of monthly cases globally since November 2022. Rising trends have been reported in the WHO African, European and Western Pacific regions. Meanwhile, the Region of the Americas has seen a decrease in cases in August 2024 compared to the previous month.
- In the past month, one new country, Gabon, reported their first mpox case.
- Five countries in Africa (Burundi, the Democratic Republic of the Congo, Kenya, Rwanda and Uganda) and two countries outside of Africa (Sweden and Thailand) have reported clade Ib

- monkeypox virus (MPXV). Available information suggests that sustained community transmission of this strain is ongoing in the Democratic Republic of the Congo and Burundi.
- The report provides operational updates about the WHO global mpox response as of 15 September 2024.
- The special focus of this edition provides an overview of a WHO mpox transmission protocol with aims to investigate mpox outbreaks in a standardized manner, enhancing control efforts and addressing critical knowledge gaps.

# ...5. Access to and delivery of countermeasures

Prequalification and Emergency Use Listing of vaccines and diagnostics

As reported previously, WHO announced the prequalification of MVA-BN vaccine on 13 September 2024 for use in adults aged 18 years and over. On 19 September, the European Medicines Agency issued new recommendations extending the indication for MVA-BN vaccines to adolescents aged 12 to 17 years. This recommendation was based on the interim results of a study that compared the immune response (production of virus-specific antibodies) in 315 adolescents compared to the response in 211 adults.

The assessment of LC16 vaccine for Emergency Use Listing is in progress. A Technical Advisory Group meeting will be held by the end of September 2024. Submission of data by the manufacturer of ACAM2000 is also expected by the end of September.

The WHO Global Advisory Committee on Vaccine Safety met on 20 September to review available safety data on mpox vaccines and country preparedness for safety monitoring among other topics. A report of the meeting will be made available.

As of 18 September, six diagnostics manufacturers have expressed their interest in EUL assessment. On 17 September, WHO received the first regulatory data and information on diagnostics from a manufacturer for EUL assessment.

**Table 1.** Number of cumulative laboratory-confirmed mpox cases and deaths reported to WHO, by WHO Region, from 1 January 2022 through 31 August 2024

WHO Region	Total confirmed cases	Total deaths among confirmed cases	New cases reported in July 2024	New cases reported in August 2024	Monthly change in cases (%)
Region of the Americas	64 879	148	447	207	-54.0
European Region	27 965	9	151	285	89.0
African Region	7662	54	1016	1298	28.0
Western Pacific Region	3979	10	163	274	68.0
South-East Asia Region	956	11	15	16	6.7
Eastern Mediterranean Region	869	2	9	2	-78.0
Total	106 310	234	1801	2082	15.6

# <u>UNICEF signs mpox vaccine deal at lowest market price for 77 low- and lower-middle-income countries</u>

NEW YORK/COPENHAGEN, 26 September 2024 – UNICEF has signed an agreement that secures supply of the MVA-BN mpox vaccine at the lowest market price and ensures access to the vaccine for 77 low-and lower-middle-income countries. **This marks a major milestone in efforts to meet the demand for more affordable vaccines as part of an integrated response to the rising mpox crisis**, while also paving the way for sustained vaccine access in 2025.

The agreement is an outcome of the <u>emergency tender</u> <u>issued by UNICEF on 29 August</u> and follows the <u>World Health Organization (WHO)'s prequalification</u> of the MVA-BN mpox vaccine on 13 September. The tender was launched two weeks after mpox was declared a public health emergency on 14 August, in collaboration with Africa CDC, Gavi, the Vaccine Alliance, WHO, the Pan American Health Organization, and other partners.

In the agreement, UNICEF has negotiated a price of up to US\$65 per vaccine dose, the lowest price in the market. The agreement also ensures vaccine access for 77 low- and lower-middle-income countries, including the Democratic Republic of the Congo (DRC) and other countries at the frontlines of the crisis.

Under the emergency tender, UNICEF is reviewing additional proposals with a view to ensuring a long-term, diversified and secured supply of mpox vaccines from more than one manufacturer at the best possible price, and with the same price transparency principles. UNICEF is also assessing the evolving vaccine demand beyond the current acute outbreak requirements.

The deal includes a firm commitment by UNICEF to procure and deliver up to 1 million doses of the MVA-BN mpox vaccine in 2024 with financial backing from partners, including 500,000 doses backed by Gavi, the Vaccine Alliance, through a complementary Advance Purchase Agreement.

::::::

#### **Clinical Research**

#### **WHO – Guidance for best practices for clinical trials**

25 September 2024 | *Guideline* Download (5.8 MB)

Overview

This document responds to requests by the World Health Assembly to the Director-General in resolution WHA75.8 (2022) on strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination to identify and propose best practices and other measures to strengthen the global clinical trial ecosystem and to review existing guidance and develop new guidance as needed on best practices for clinical trials. This guidance updates and adapts the previous work of the World Health Organization (WHO) on research capacity for the context of well-designed and well-implemented clinical trials as framed in resolution WHA75.8 (2022). It aims to enhance clinical research efficiency, minimize research waste and provide guidance on sustained clinical trials that are always functional and active for endemic conditions and can pivot in time of emergency or pandemics.

# [Excerpts from news release]

...The guidance includes practical considerations for setting up trials to include pregnant and lactating women, given they have unique healthcare needs. In general, at-risk populations should be involved from the earliest stages. To facilitate this, safety should be assessed as an initial priority, for instance,

by reviewing comparable interventions or expediting pre-clinical studies for these groups. Appropriate procedures for consent and assent are key, particularly for children.

The guidance recommends putting patient, participant and community engagement at the heart of organizing clinical trials, to ensure that research planning, delivery and dissemination meets public needs and maintains trust.

The new guidance also seeks to strengthen national R&D ecosystems through sustainable financing, to support better decision-making, accelerate access to health innovation and build more robust and effective national and global health research environments.

The guidance was developed in response to World Health Assembly resolution <u>WHA 75.8</u> in an extensive and inclusive process, involving nearly 3000 stakeholders from various sectors across 48 countries...

::::::

#### **Featured Journal Content**

#### **Nature Human Behaviour**

Volume 8 Issue 9, September 2024 https://www.nature.com/nathumbehav/volumes/8/issues/9 Article 01 Aug 2024

A systematic review and meta-analysis of strategies to promote vaccination uptake

Sicong Liu, Marta R. Durantini, Dolores Albarracin *Abstract* 

Although immunization can dramatically curb the mortality and morbidity associated with vaccine-preventable diseases, vaccination uptake remains suboptimal in many areas of the world. Here, in this meta-analysis, we analysed the results from 88 eligible randomized controlled trials testing interventions to increase vaccination uptake with 1,628,768 participants from 17 countries with variable development levels (for example, Human Development Index ranging from 0.485 to 0.955). We estimated the efficacy of seven intervention strategies including increasing access to vaccination, sending vaccination reminders, providing incentives, supplying information, correcting misinformation, promoting both active and passive motivation and teaching behavioural skills. We showed that the odds of vaccination were 1.5 (95% confidence interval, 1.27 to 1.77) times higher for intervention than control conditions. Among the intervention strategies, using incentives and increasing access were most promising in improving vaccination uptake, with the access strategy being particularly effective in countries with lower incomes and less access to healthcare.

::::::

#### Polio - PHEIC

# Polio this week as of 25 September 2024 - GPEI

Headlines

:: The latest Independent Monitoring Board (IMB) report has been finalized, following the group's meeting in July in Geneva. The IMB continues to provide crucial, independent analysis of the programme and puts forth recommendations to address remaining challenges. <u>More</u>.

:: GPEI welcomes and appreciates Canada's pledge of CAD \$151 million to achieve the eradication of polio and build stronger health systems worldwide. <u>More.</u>

# Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: four WPV1 cases

Democratic Republic of the Congo: two cVDPV2 cases

Niger: two cVDPV2-positive environmental samples

Nigeria: four cVDPV2 cases

::::::

# 23rd Report :: Independent Monitoring Board - GPEI

# The Long Goodbye - Poliovirus Continues to Resist Extinction

September 2024 :: 103 pages

[Concludes with 17 recommended actions across all areas of the GPEI programme, p.95 ff]

::::::

# **GPEI Welcomes 23rd Annual Report from the Independent Monitoring Board** 24/09/2024

The IMB's latest report notes the promising decline of types 1 and 2 variant poliovirus cases globally in the past year and the strong regional commitment to eradication throughout the Eastern Mediterranean Region. That said, the program agrees with the IMB's assessment that progress against variant poliovirus to date is extremely fragile and variable across geographies, and that the recent rise in wild poliovirus detections in Pakistan and Afghanistan is of serious concern.

The IMB also rightly recognizes the incredibly complex environments where the virus remains and the external factors impeding the program's ability to consistently reach children in these places. The GPEI appreciates the board's frank assessment of management and campaign quality challenges that the program is aware of and proactively working to address.

As the IMB previews, the GPEI, after critical analysis and expert consultations, has decided to extend the timeline of certifying the eradication of wild polio to 2027 and certifying the elimination of type 2 variant polio to 2029. The GPEI will soon be releasing a document outlining the key tactical shifts that it will implement to enable stronger accountability and ownership across all levels of the program during this period. This also includes a more systematic approach to integrating polio activities with other health services and improving coordination with essential immunization programs to set the foundation to sustain a polio-free world....

::::::

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

#### WHO & Regional Offices [to 21 Sep 2024]

https://www.who.int/news

Selected News/Announcements/Statements

27 September 2024 News release

Recommendations announced for influenza vaccine composition for the 2025 southern hemisphere influenza season

26 September 2024 News release

WHO and TikTok to collaborate on more science-based information on health and wellbeing

26 September 2024 *Joint News Release* 

World leaders commit to decisive action on antimicrobial resistance

25 September 2024 News release

New global guidance puts forward recommendations for more effective and equitable clinical trials

23 September 2024 *Joint News Release* 

WHO and multilateral development banks kick off €1.5 billion primary health financing platform with new funds and launch of first investment plans in 15 countries

23 September 2024 News release

Boosting digital health can help prevent millions of deaths from noncommunicable diseases

::::::

# **WHO Regional Offices**

Selected Press Releases, Announcements

# **WHO African Region**

:: 27 September 2024

**Joint statement: World Rabies Day** 

:: 26 September 2024

**Experts agree on African regional plan for health and climate change** 

:: 24 September 2024

WHO in Africa, IFRC bolster partnership for enhanced public health emergency response

:: 24 September 2024

Kenya steps up surveillance, response measures to curb mpox

#### **WHO Region of the Americas PAHO**

:: 26 Sep 2024

# <u>PAHO and Pro Mujer sign agreement to improve women's health in Latin America and the Caribbean</u>

New York, September 26, 2024 (PAHO) - The Pan American Health Organization (PAHO) and Pro Mujer today signed a Memorandum of Understanding to implement joint actions to improve the health conditions of women in vulnerable situations in Latin America and the Caribbean, with a specific focus on interculturality and ethnicity. This collaboration seeks...

:: 26 Sep 2024

# <u>PAHO and GARDP will collaborate to tackle antibiotic resistance in Latin America and the Caribbean</u>

New York, 26 September 2024 – The Pan American Health Organization (PAHO) and the Global Antibiotic Research & Development Partnership (GARDP) have signed an agreement to collaborate in the response to antimicrobial resistance (AMR) in Latin America and the Caribbean. Under the agreement, the organizations aim to improve regional...

:: 26 Sep 2024

HPV testing and single-dose vaccine key to tackle cervical cancer in the Americas, PAHO report says

Washington D.C. 26 September 2024 (PAHO) – A new report on cervical cancer in the region of the Americas launched today by the Pan American Health Organization (PAHO) urges countries to implement new innovations in cervical cancer prevention, testing and treatment, to help close gaps and get on track to achieve the elimination goals by 2030....

:: 25 Sep 2024

# <u>PAHO Director highlights importance of a global, solidarity-based and equitable response to antimicrobial resistance</u>

New York, September 25, 2024 (PAHO) – The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, made an urgent call to the international community to address the growing threat of antimicrobial resistance (AMR) in a solidarity-based and equitable manner. During his speech at a side event prior to the United Nations High-...

:: 25 Sep 2024

# PAHO and IDB sign agreement to broaden collaboration

New York, 25 September 2024 — The Pan American Health Organization (PAHO) and the Inter-American Development Bank (IDB) signed a new framework agreement that marks a significant step in their partnership. This agreement enables both PAHO and IDB to broaden their collaboration, which grew considerably as a result of the COVID-19 pandemic, fostering...

:: 24 Sep 2024

# PAHO Director calls for urgent action to eliminate cervical cancer in the Americas

New York, 24 September 2024 (PAHO) – The Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa, today called on partners and donors to support countries of the Americas to address the "unacceptable" number of cervical cancer cases and deaths. Almost 80,000 women in the Region are affected each year, highlighting the need for...

#### **WHO South-East Asia Region SEARO**

No new digest content identified.

# WHO European Region EURO

No new digest content identified.

# WHO Eastern Mediterranean Region EMRO

:: Finding ways to stop the spread of polio amid Sudan's protracted conflict 24 September 2024

# **WHO Western Pacific Region**

No new digest content identified.

::::::

# WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

Multi-country outbreak of mpox, External situation report #37 - 22 September 2024

::::::

#### **Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new DONs identified.

::::::

# **Weekly Epidemiological Record**

https://www.who.int/publications/journals/weekly-epidemiological-record

Vol. 99, No. 39, pp. 545-564 27 September 2024

PDF: https://iris.who.int/bitstream/handle/10665/379056/WER9939-eng-fre.pdf

:: Progress in eliminating onchocerciasis in the WHO Region of the Americas: Report from the Inter-American Conference on Onchocerciasis (IACO) 2023

:: Control of epidemic meningitis in countries in the African meningitis belt, 2023

::::::

#### **New WHO Publications**

https://www.who.int/publications/i

Selected

26 September 2024

WHO Technical Advisory Group on the responsible use of the life sciences and dual-use research: report...

25 September 2024

<u>Tackling malaria in countries hardest hit by the disease: ministerial conference report,</u> Yaoundé, Cameroon,...

25 September 2024

Manual for plague surveillance, diagnosis, prevention and control

25 September 2024

**Guidance for best practices for clinical trials** 

24 September 2024

Maternal, newborn, child, adolescent health and ageing and quality of care indicator metadata toolkit

24 September 2024

**Developing national meningitis plans: an operational manual** 

24 September 2024

Diagnosis of tuberculosis and detection of drug-resistance: rapid communication

23 September 2024

<u>Country experiences on subnational verification of malaria elimination: roundtable meeting report, 14...</u>

23 September 2024

<u>Water, sanitation and hygiene and infection prevention and control measures for infectious diarrhoea...</u>

::::::

**USA – HHS, FDA, CDC** 

#### HHS

News

Readout of Secretary Becerra's Meeting with WHO and Africa CDC on Mpox

September 27, 2024 News Release

HHS Invests in Project to Accelerate the Discovery and Development of New Antibiotics
Using Generative AI

September 26, 2024 News Release

Remarks by Secretary Xavier Becerra at the 2024 UN General Assembly High-Level Meeting on Antimicrobial Resistance

September 26, 2024 Speech

**HHS Announces Mpox Vaccine Donations, Boosting Domestic and International Supply** 

September 24, 2024 News Release

These actions increase domestic and international preparedness and include the largest international donation of JYNNEOS to date

Today, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), announced actions to increase the supply of mpox vaccine, supporting the U.S. Government commitment to make over a million combined doses of mpox vaccines available to the global mpox response. This is the largest international donation of the JYNNEOS mpox vaccine to date, which just received regulatory approval from WHO last week.

#### **FDA**

Press Announcements

News

No new digest content identified.

### **FDA VRBPAC**

<u>Advisory Committee Calendar</u> No new meetings identified.

**CDC/ACIP [U.S.]** [to 21 Sep 2024]

http://www.cdc.gov/media/index.html

Latest News

No new digest content identified.

#### **ACIP Meetings**

Next ACIP Meeting
October 23-24, 2024

# **MMWR Weekly**

https://www.cdc.gov/mmwr/index2023.html

September 26, 2024 / No. 38

### **PDF of this issue**

- <u>COVID-19–Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months —</u> COVID-NET, 12 States, October 2022–April 2024
- <u>Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody</u> (Nirsevimab) by Infants Aged <8 Months United States, April 2024
- <u>Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born</u> in 2020 and 2021 National Immunization Survey-Child, United States, 2021–2023

- Vaccination Coverage by Age 24 Months Among Children Born During 2017–2021 — U.SAffiliated Pacific Islands
:::::: :::::
Europe
European Medicines Agency [EMA]  https://www.ema.europa.eu/en/news  News & Press Releases  No new digest content identified.
European Centre for Disease Prevention and Control <a href="https://www.ecdc.europa.eu/en">https://www.ecdc.europa.eu/en</a> <a href="https://www.ecdc.europa.eu/en">News/Updates/Reports/Publications [Selected]</a> <a href="https://www.ecdc.europa.eu/en">Surveillance and monitoring [Selected]</a> <a href="https://www.ecdc.europa.eu/en">Surveillance and monitoring [Selected]</a> <a href="https://www.ecdc.europa.eu/en">Surveillance and monitoring [Selected]</a> <a href="https://www.ecdc.europa.eu/en">Monthly measles and rubella monitoring report - July 2024</a> <a href="https://www.ecdc.europa.eu/en">26 Sep 2024</a> <a href="https://www.ecdc.europa.eu/en">This report provides an overview of measles and rubella cases reported to ECDC through The European Surveillance System"&gt;European Surveillance System</a> (TESSy).
:::::: ::::::
Africa CDC [to 21 Sep 2024]  https://africacdc.org/ Press Releases, Statements [Selected]  Communique of 3rd Meeting of the Committee of Heads of State and Government of the Africa Centres for Disease Control and Prevention (Africa CDC)  23 September 2024  The Heads of State and Covernment reaffirmed their committee on the centing for

... The Heads of State and Government reaffirmed their commitment to continue advocating for support from all sectors, underlining the importance of collective responsibility and solidarity in overcoming the public health challenges posed by the Mpox epidemic....

#### Press Releases

# Africa CDC Statement on the Pandemic Fund's Fast-Track Allocation of US\$128.89 Million to Address Mpox in 10 Countries

Addis Ababa, ETHIOPIA – September 21, 2024: Africa Centres for Disease Control and Prevention (Africa CDC) expresses its deep gratitude and commendation for the Pandemic Fund's decisive action to fast-track US\$128.89 million to 10 African Union Member States affected by mpox. This timely allocation demonstrates the global community's commitment to addressing the continent's pressing health security challenges...

::::::

#### **China CDC**

http://www.chinacdc.cn/en/

**National Health Commission of the People's Republic of China** [to 21 Sep 2024] http://en.nhc.gov.cn/

News

No new digest content identified.

# National Medical Products Administration – PRC [to 21 Sep 2024]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC CCDC Weekly Reports: Current Volume (6) 2024-09-27 / No. 39

PDF of this issue

::::::

# Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

# **Organization Announcements**

# Paul G. Allen Frontiers Group [to 21 Sep 2024]

https://alleninstitute.org/news-press/

News

No new digest content identified.

# **BMGF - Gates Foundation** [to 21 Sep 2024]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements Press release Sep 24, 2024

<u>European Union and Bill & Melinda Gates Foundation Partner to Expand Contraceptive and Health Access for Women in Low- and Middle-Income Countries</u>

Press release Sep 23, 2024

<u>Gates Foundation Celebrates Children's Health and Nutrition Champions at Goalkeepers</u> **2024:** Recipe for Progress

#### **Bill & Melinda Gates Medical Research Institute** [to 21 Sep 2024]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications No new digest content identified.

**CARB-X** [to 21 Sep 2024]

https://carb-x.org/

News

09.27.2024 |

# **CARB-X to support implementation of Political Declaration on AMR**

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) welcomes the widespread support expressed by United Nations (UN) Member States to the Political Declaration on antimicrobial resistance (AMR) during the High-Level Meeting which took place yesterday (Thursday, September 26, 2024) at the 79th Session of the UN General Assembly (UNGA 79). No new digest content identified.

# **CEPI – Coalition for Epidemic Preparedness Innovations** [to 21 Sep 2024]

http://cepi.net/

CEPI News

News

#### **CEPI** puts new biosecurity strategy at heart of 100 Days Mission

24 Sep 2024

News

# <u>PAHO and CEPI to advance regulatory harmonization and response to health emergencies</u> in the Americas

22 Sep 2024

#### CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 21

Sep 20241

https://cioms.ch/

News; Publications; Events

No new digest content identified.

#### DARPA - Defense Advanced Research Projects Agency [U.S.] [to 21 Sep 2024

https://www.darpa.mil/news

News

No new digest content identified.

# **Duke Global Health Innovation Center** [to 21 Sep 2024]

https://dukeghic.org/

News

No new digest content identified.

# **EDCTP** [to 21 Sep 2024]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS,

tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials News

24 September 2024

### **Eswatini joins EDCTP Association**

EDCTP is pleased to welcome Eswatini on board as the newest member country of the EDCTP Association, bringing the total number of African countries to 29.

# **Emory Vaccine Center** [to 21 Sep 2024]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

# **European Vaccine Initiative** [to 21 Sep 2024]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

# Evidence Aid [to 21 Sep 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

http://www.evidenceaid.org/

Resources [Selected]

No new digest content identified.

#### Fondation Merieux [to 21 Sep 2024]

http://www.fondation-merieux.org/ News, Events

No new digest content identified.

**Gavi** [to 21 Sep 2024] https://www.gavi.org/ Press Releases

No new digest content identified.

# **GE2P2 Global Foundation** [to 21 Sep 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review June 2024
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 10 Sep 2024 Issue 23

# **GHIT Fund** [to 21 Sep 2024]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

# **Global Fund** [to 28 Sep 2024]

https://www.theglobalfund.org/en/news/

25 September 2024

#### Global Fund Approves Nearly US\$1 Million for Uganda's Mpox Response

At the request of the government of Uganda, the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has approved the reinvestment of US\$850,683 to enhance the country's capacity to prevent, detect and respond to the current mpox out...

# **Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 21 Sep

2024]

https://www.glopid-r.org/new s/

News

No new digest content identified.

# Hilleman Laboratories [to 21 Sep 2024]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

# **HHMI - Howard Hughes Medical Institute** [to 21 Sep 2024]

https://www.hhmi.org/news

Press Room

No new digest content identified.

# **Human Immunome Project [nee Human Vaccines Project]** [to 21 Sep 2024]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

**IAVI** [to 21 Sep 2024]

https://www.iavi.org/

News, Features

Press Releases

# Africa CDC and IAVI sign Memorandum of Understanding to enhance vaccine and antibody research capacity in Africa

September 25, 2024

Partnership also to include efforts to strengthen the continent's disease-fighting capacity, pandemic readiness, and supply resilience

**INSERM** [to 21 Sep 2024]

https://www.inserm.fr/en/home/

Press Releases

No new digest content identified.

# **International Coalition of Medicines Regulatory Authorities [ICMRA]**

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

# ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 28 Sep 2024]

https://www.ich.org/ News/Pubs/Press Releases [Selective] 25 September 2024

# The ICH E11A Introductory Training Presentation is now available on the ICH website.

Following the adoption of the E11A Guideline, a Step 4 Introductory Training Presentation has been developed by the E11A Expert Working Group.

The E11A Guideline provides recommendations and promotes international harmonisation of paediatric extrapolation to support the development and authorisation of paediatric medicines. The E11A Guideline provides a framework for using extrapolation to support paediatric drug development.

ICRC [to 21 Sep 2024]
https://www.icrc.org/en/whats-new
What's New [Selected]
No new digest content identified.

#### **IFFIm**

http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

IFRC [to 21 Sep 2024] http://media.ifrc.org/ifrc/news/press-releases/ Press Releases [Selected] No new digest content identified.

**Institut Pasteur** [to 21 Sep 2024] https://www.pasteur.fr/en/press-area Press Documents
No new digest content identified.

#### **ISC / International Science Council** [to 21 Sep 2024]

https://council.science/current/ Latest Updates News 26 September 2024

News 20 September 2024

**Announcing the ISC Expert Group for the Biological Weapons Convention** 

**International Union of Immunological Societies (IUIS)** 

https://iuis.org/ News/Events [Selected] No new digest content identified.

**IVAC** [to 21 Sep 2024]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

**IVI** [to 21 Sep 2024]

http://www.ivi.int/

IVI News & Announcements

# IVI's Global Advisory Group of Experts welcomes 5 new distinguished members

The Global Advisory Group of Experts (GAGE) of the International Vaccine Institute (IVI) welcomes five distinguished leaders from diplomacy, global health, and the business community as new members. The group, inaugurated in 2022, held its third annual meeting in Bangkok, Thailand, on September 24, 2024.

Currently chaired by Dr. Anders Nordström of Sweden, the GAGE previously had <u>five members</u> following the departures of its inaugural chair Dr. Deborah Birx, CEO of Armata Pharmaceuticals, who has since joined IVI's Board of Trustees, and Dr. Kang Kyung-wha, former Minister of Foreign Affairs of the Republic of Korea, who assumed the chair of the Asia Society.

Mr. George Bickerstaff, Chair of the IVI Board of Trustees, said: "We warmly welcome Dr. Park Jin, Dr. Ayoade Alakija, Dr. Mark Dybul, Ms. Revathi Rammohan, and Prof. Peter Piot as new GAGE members. They bring extraordinary leadership and profound expertise across diplomacy, industry, and the broader global health community. IVI will greatly benefit from their vision and guidance."...

#### **Johns Hopkins Center for Health Security** [to 21 Sep 2024]

https://centerforhealthsecurity.org/newsroom
Center News [Selected]
No new digest content identified.

#### MSF/Médecins Sans Frontières [to 21 Sep 2024]

http://www.msf.org/ Latest [Selected Announcements] Antibiotic resistance

Concrete action needed in fight against antimicrobial resistance

Press Release 25 Sep 2024

# National Academy of Medicine - USA [to 28 Sep 2024]

https://nam.edu/programs/

News [Selected]

NAM Leaders Join High-Level Meetings to Address Global Health Challenges; Speak at Events Focused on Climate Change, Women's Health, Regional Vaccine Manufacturing September 23, 2024

https://www.nationalacademies.org/newsroom?

News

# **New Rapid Expert Consultation: Childhood Immunization**

Childhood vaccines have the long-established benefits of preventing illness and averting death. A new rapid expert consultation identifies key strategies for promoting vaccination, such as reminders, convenience, and tailored messaging that takes culture and beliefs into account. 09/24/2024

# National Vaccine Program Office - U.S. HHS [to 21 Sep 2024]

https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates No new digest content identified.

**NIH** [to 28 Sep 2024] http://www.nih.gov/

**Statement by NIH on Research Misconduct Findings** 

September 26, 2024 — NIH takes very seriously allegations of research misconduct.

#### NIH awards \$27M to establish new network of genomics-enabled learning health systems

Network will analyze and improve how genomic information is integrated into patient care. Monday, September 23, 2024

**PATH** [to 21 Sep 2024] <a href="https://www.path.org/media-center/Newsroom">https://www.path.org/media-center/Newsroom</a>
No new digest content identified.

# **Sabin Vaccine Institute** [to 21 Sep 2024]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

**UNAIDS** [to 21 Sep 2024]

http://www.unaids.org/en News, Stories, Updates Press release

# The AIDS response is recognized as a beacon of hope and guide for revitalizing multilateralism at the 79th UN General Assembly

NEW YORK/GENEVA, 27 September 2024—At the <u>79th United Nations General Assembly</u> (UNGA79) and the <u>Summit of the Future</u> in New York, global leaders called for the revitalization of multilateralism to address pressing global crises, drawing on the success of the global AIDS response as a model of hope and global solidarity.

Press release

#### Leaders pledge bold action to end AIDS by 2030

Global leaders unite to recommit to ending AIDS during the 79th United Nations General Assembly in New York

**UNICEF** [to 21 Sep 2024]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements

*News note* 26 September 2024

<u>UNICEF signs mpox vaccine deal at lowest market price for 77 low- and lower-middle-income countries</u>

NEW YORK/COPENHAGEN, 26 September 2024 – UNICEF has signed an agreement that secures supply of the MVA-BN mpox vaccine at the lowest market price and ensures access to the vaccine for 77 low- and lower-middle-income countries. This marks a major milestone in efforts to meet the demand for more affordable vaccines as part of an integrated response...

Statement 23 September 2024

<u>Statement by Principals of Inter-Agency Standing Committee (IASC) on Israel and Occupied Palestinian Territory</u>

NEW YORK/GENEVA/ROME/WASHINGTON, 23 September 2024 — "As world leaders gather in New York for the 79th United Nations General Assembly, and as the threat of a wider regional escalation looms, we renew our demand for an end to the appalling human suffering and humanitarian catastrophe in Gaza. "We mourn the loss of...

**Unitaid** [to 21 Sep 2024]

https://unitaid.org/

Featured News

25 September 2024

New Unitaid report calls for more effective, affordable gonorrhea diagnostics to address rising infections and antimicrobial resistance

25 September 2024

Donor statement on urgent action required to address antimalarial drug resistance

23 September 2024

<u>Unitaid launches report on tools and interventions for diagnosis and management of pre-eclampsia, a major driver of maternal mortality</u>

23 September 2024

<u>Partnership critical to reducing maternal mortality, says Sierra Leonean Minister of Health, welcoming Unitaid report</u>

**Vaccine Equity Cooperative [nee Initiative]** [to 21 Sep 2024]

https://vaccineequitycooperative.org/news/

News

Website not responding at inquiry.

**Vaccination Acceptance & Demand Initiative [Sabin)** [to 21 Sep 2024]

https://www.vaccineacceptance.org/

Announcements, Blog

No new digest content identified.

# **Vaccine Confidence Project** [to 21 Sep 2024]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

# **Vaccine Education Center – Children's Hospital of Philadelphia** [to 21 Sep 2024]

http://www.chop.edu/centers-programs/vaccine-education-center

News

# **Vaccine Update for Providers**

September 2024

Announcements: AAP 2024, webinar recording, print-on-demand program, discussing COVID-19 vaccine this fall

# Wellcome Trust [to 21 Sep 2024]

https://wellcome.org/news/all
News. Opinion, Reports
No new digest content identified.

# **The Wistar Institute** [to 21 Sep 2024]

https://www.wistar.org/news/press-releases Press Releases No new digest content identified.

World Bank [to 21 Sep 2024]
http://www.worldbank.org/en/news/all
All News [Selected]
Selected Press Releases
No new digest content identified.

#### WFPHA: World Federation of Public Health Associations [to 21 Sep 2024]

https://www.wfpha.org/

Blog, Events

# **Expanding HPV Vaccination in Cameroon**

Sep 24, 2024

# World Medical Association [WMA] [to 28 Sep 2024]

https://www.wma.net/news-press/press-releases/

Press Releases

# On World Rabies Day, WVA and WMA unite to call for "Breaking Rabies Boundaries"

To mark World Rabies Day on 28 September 2024, the World Veterinary Association (WVA) and the World Medical Association (WMA) demand continued efforts to eradicate rabies. Under the theme "Breaking Rabies Boundaries", the two organisations advocate for a One Health approach, vaccination for high-risk groups, and universal access to rabies treatment.

Rabies, a fatal yet preventable disease, is estimated to cause <u>59 000</u> human deaths a year across 150 countries, according to the World Health Organization. 95% of cases occur in Africa and Asia. This makes it a significant public health threat in those regions.

The WVA and the WMA in their support for a One Health approach, call for actions that emphasize the interconnectedness of human, animal, and environmental health in the fight to break the cycle of rabies transmission...

"Rabies vaccination is a powerful preventive measure for people living in areas where rabies is prevalent or those likely to come into contact with rabies-infected animals, like veterinarians, animal handlers and travellers to affected regions."...

# World Organisation for Animal Health [OIE] [to 21 Sep 2024]

https://www.oie.int/ Press Releases, Statements Website not responding at inquiry.

::::::

# ARM [Alliance for Regenerative Medicine] [to 21 Sep 2024]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

**BIO** [to 21 Sep 2024]

https://www.bio.org/press-releases

Press Releases

No new digest announcements identified.

# **DCVMN – Developing Country Vaccine Manufacturers Network** [to 21 Sep 2024]

http://www.dcvmn.org/
News; Upcoming events

**ANNUAL GENERAL MEETING 2024** 

October 16 - 18, 2024 São Paulo, Brazil

#### ICBA – International Council of Biotechnology Associations [to 21 Sep 2024]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

**IFPMA** [to 21 Sep 2024]

https://ifpma.org/

News, Statements [Selected] Statement 26 Sep 2024

# Statement from IFPMA at UN HLM on AMR 2024

On 26 September 2024, IFPMA submitted the following statement from the floor at the UN High-Level Meeting on AMR. Eight years after the first ever AMR high-level meeting we find ourselves at the precipice of turning the tide. The pharmaceutical industry heard the call to action at the first high-level meeting, and through establishing the...

# **International Alliance of Patients' Organizations – IAPO** [to 21 Sep 2024]

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

# **International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News

No new digest announcements identified.

**PhRMA** [to 21 Sep 2024]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

# Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

#### **AstraZeneca**

<u>Press Releases</u> - No new digest announcements identified

#### **Bavarian Nordic**

Latest News

September 26, 2024

#### **Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines**

First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa

September 24, 2024

<u>Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines</u>

#### **Bharat Biotech**

<u>Press Releases</u> - No new digest announcements identified

# BioCubaFarma - Cuba

<u>Últimas Noticias</u> - No new digest announcements identified

#### **Biological E**

News - No new digest announcements identified

#### **BioNTech**

Press Releases - No new digest announcements identified

#### **Boehringer**

<u>Press Releases</u> - No new digest announcements identified

#### **CanSinoBIO**

News - Website not responding at inquiry

#### **CIGB**

<u>Latest News</u> - No new digest announcements identified.

# Cinnagen

Recent News - No new digest announcements identified.

# **Clover Biopharmaceuticals** – China

<u>News</u> - No new digest announcements identified.

# **Curevac**

News - No new digest announcements identified.

#### **Gamaleya National Center/Sputnik**

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

#### **GSK**

<u>Press releases for media</u>

24 September 2024

GSK's Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion

Marketing authorisation in EU expected by November 2024.

#### **EuBiologics,** S Korea

News - No new digest announcements identified.

# IMBCAMS, China

Home - Website not responding at inquiry.

#### Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified.

#### Merck

News releases - No new digest announcements identified.

#### Moderna

Press Releases - No new digest announcements identified

#### Nanogen

News - No new digest announcements identified

#### **Novartis**

<u>News</u> - No new digest announcements identified.

#### Novavax

Press Releases

Sep 25, 2024

Corporate and finance

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

#### **Pfizer**

Recent Press Releases

09.25.2024

<u>Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA®</u> (voxelotor) From Worldwide Markets

#### **R-Pharm**

https://rpharm-us.com/index.php
[No news or media page identified]

#### **Sanofi Pasteur**

Press Releases - No new digest announcements identified

# **Serum Institute of India**

<u>NEWS & ANNOUNCEMENTS</u> - No new digest announcements identified

# Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified

#### Sinovac

<u>Press Releases</u> - No new digest announcements identified.

#### **SK Biosciences**

<u>Press Releases</u> - No new digest announcements identified.

#### **Takeda**

<u>Newsroom</u> - No new digest announcements identified.

#### **Valneva**

<u>Press Releases</u> - No new digest announcements identified.

# **Vector State Research Centre of Viralogy and Biotechnology**

<u>Home</u> - [Website not responding [404 error]

#### WestVac Biopharma

Media - No new digest announcements identified.

# Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch

:: <u>Pre-Print Servers</u>

::::::

#### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

# **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 3 <a href="https://www.tandfonline.com/toc/uabr21/current">https://www.tandfonline.com/toc/uabr21/current</a> [Reviewed earlier]

#### **AMA Journal of Ethics**

Volume 26, Number 9: E665-744

https://journalofethics.ama-assn.org/issue/nonhuman-animal-research

#### Nonhuman Animal Research

Nonhuman animals have long been and continue to be routinely used in biomedical and behavioral research to promote human health. When SARS-CoV2 infections triggered a race to develop and scale global access to vaccines in 2019, two key innovations happened to the supply chain of nonhuman animals created, raised, and used for science: (1) experiments and trials regarded as essential were prioritized and (2) governments and researchers shortened vaccine production timelines. Clinical and public health urgency concentrated and acutely focused demand for live mammals—especially ferrets, guinea pigs, hamsters, mice, nonhuman primates, pigs, and rats—in ways that also intensified demand for efficient protocol designs and streamlined methods of human vaccine research and development. Reasonable people can still disagree about when, why, and how nonhuman animals should be sacrificed for human health, but we now know that human health endeavors, specifically vaccine development, flourish even when we sanction fewer nonhuman animals' cultivation and deaths for science. This theme issue investigates what this revelation from the pandemic means from clinical, ethical, legal, and policy standpoints for the future of human-centered research.

#### **American Journal of Human Genetics**

Sep 05, 2024 Volume 111 Issue 9 p1797-2070 https://www.cell.com/ajhg/current

This Month in *The Journal* 

Alyson B. Barnes, Kylee L. Spencer

Proteogenomics draws on the fields of genomics, transcriptomics, and proteomics to discern how genetic variation influences the set of proteins produced by a cell with the goal of elucidating how this relates to disease risk. Although colocalization approaches can be used to identify variants that are tied to both splicing and disease, the limitations of short-read RNA sequencing have often prevented determining which protein isoform or group of isoforms specifically mediates risk. In this issue, Abood et al.

# [Reviewed earlier]

#### **American Journal of Infection Control**

September 2024 Volume 52 Issue 9 p985-1104 <a href="http://www.ajicjournal.org/current">http://www.ajicjournal.org/current</a> [Reviewed earlier]

#### **American Journal of Preventive Medicine**

September 2024 Volume 6 7 Issue 3 p319-476 https://www.ajpmonline.org/current [Reviewed earlier]

### **American Journal of Public Health**

October 2024 114(109) http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

# **American Journal of Tropical Medicine and Hygiene**

Volume 111 (2024): Issue 3 (Sep 2024) <a href="https://www.ajtmh.org/view/journals/tpmd/111/3/tpmd.111.issue-3.xml">https://www.ajtmh.org/view/journals/tpmd/111/3/tpmd.111.issue-3.xml</a> [Reviewed earlier]

#### **Annals of Internal Medicine**

September 2024 Volume 177, Issue 9 <a href="https://www.acpjournals.org/toc/aim/current">https://www.acpjournals.org/toc/aim/current</a> [Reviewed earlier]

# **Artificial Intelligence – An International Journal**

Volume 334 September 2024 <a href="https://www.sciencedirect.com/journal/artificial-intelligence/vol/334/suppl/C">https://www.sciencedirect.com/journal/artificial-intelligence/vol/334/suppl/C</a> [Reviewed earlier]

#### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 21 Sep 2024) [No new digest content identified]

# **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 21 Sep 2024)

Awareness of, willingness to use, and experiences with Pre-exposure prophylaxis among youth in Nigeria

Youth (ages 14–24) in Nigeria have disproportionately high rates of new HIV infection. Pre-exposure prophylaxis could substantially reduce new infections among youth but has not been scaled up. This cross-sect...

Authors: Titilola Gbaja-Biamila, Chisom Obiezu-Umeh, Ucheoma Nwaozuru, Nora E. Rosenberg, Mesoma Igbokwe, David Oladele, Adesola Z. Musa, Ifeoma Idigbe, Donaldson Conserve, Suzanne Day,

Kadija Tahlil, Jason Ong, Kathryn Muessig, Susan Nkengasong, Hong Xian, Joseph D. Tucker...

Citation: BMC Health Services Research 2024 24:1128 Content type: Research Published on: 27 September 2024

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 21 Sep 2024) [No new digest content identified]

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 21 Sep 2024)

Researchers experience and views on participants' comprehension of informed consent in clinical trials in Malawi: a descriptive qualitative study

Informed consent is the cornerstone of research ethics. One of its goals is that participants enter research with an understanding of what their participation entails. This paper is a study on how researchers ...

Authors: Dorothy Maxwell Kazembe, Yimtubezinash Woldeamanuel and Solomon Mequanente Abay

Citation: BMC Medical Ethics 2024 25:101

Content type: Research Published on: 27 September 2024

# <u>Biobanking, digital health and privacy: the choices of 1410 volunteers and neurological patients regarding limitations on use of data and biological samples, return of results and sharing</u>

The growing diffusion of artificial intelligence, data science and digital health has highlighted the role of collection of data and biological samples, thus raising legal and ethical concerns regarding its us...

Authors: Emilia Giannella, Josep Miquel Bauça, Simona Gabriella Di Santo, Stefano Brunelli, Elisabetta Costa, Sergio Di Fonzo, Francesca Romana Fusco, Antonio Perre, Valerio Pisani, Giorgia Presicce, Francesca Spanedda, Giorgio Scivoletto, Rita Formisano, Maria Grazia Grasso, Stefano Paolucci, Domenico De Angelis...

Citation: BMC Medical Ethics 2024 25:100

Content type: Research Published on: 27 September 2024

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 21 Sep 2024)

<u>Post-marketing surveillance framework of cell and gene therapy products in the European</u> Union, the United States, Japan, South Korea and China: a comparative study

Cell and gene therapy products (CGTPs) often receive accelerated approvals, lacking comprehensive long-term safety and efficacy data, which can raise significant safety concerns. This research aims to study th...

Authors: Yuxin Cai, Lijuan Sui, Jingjing Wang, Weilin Qian, Yeheng Peng, Luyao Gong, Weijia Wu and

Yuan Gao

Citation: BMC Medicine 2024 22:421

Content type: Research article Published on: 27 September 2024

# Estimating pneumococcal carriage dynamics in adults living with HIV in a mature infant pneumococcal conjugate vaccine programme in Malawi, a modelling study

Adults living with human immunodeficiency virus (ALWHIV) receiving antiretroviral therapy (ART) exhibit higher pneumococcal carriage prevalence than adults without HIV (HIV-). To assess factors influencing hig...

Authors: Joseph Phiri, Lusako Sibale, Lukerensia Mlongoti, Ndaona Mitole, Alice Kusakala, Mercy Khwiya, Thokozani Kayembe, Edwin Lisimba, Prosperina Kapwata, Ken Malisita, Chrispin Chaguza,

Daniela M. Ferreira, Deus Thindwa and Kondwani Jambo

Citation: BMC Medicine 2024 22:419

Content type: Research Published on: 27 September 2024

# **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 21 Sep 2024) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 21 Sep 2024)

# **Religious belongings and Covid-19 vaccination**

Vaccine hesitancy poses a complex global challenge. Our study investigates correlations between COVID-19 vaccination rates, religious demographics, and educational performance.

Authors: Konstantine Chakhunashvili, Eka Kvirkvelia and Davit G. Chakhunashvili

Citation: BMC Public Health 2024 24:2585

Content type: Research Published on: 27 September 2024

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 21 Sep 2024) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

October 2024 - Volume 29 - 5 https://ebm.bmj.com/content/29/5 [Reviewed earlier]

#### **BMJ Global Health**

September 2024 - Volume 9 - 9 https://gh.bmj.com/content/9/9 [Reviewed earlier]

# **Bulletin of the Atomic Scientists**

September 2024

https://thebulletin.org/magazine/2024-09/

### [Reviewed earlier]

# **Bulletin of the World Health Organization**

Volume 102(9); 2024 Sep 1 <a href="https://www.ncbi.nlm.nih.gov/pmc/issues/469680/">https://www.ncbi.nlm.nih.gov/pmc/issues/469680/</a> [Reviewed earlier]

#### Cell

Sep 05, 2024 Volume 187 Issue 18 p4813-5118 https://www.cell.com/cell/current [Reviewed earlier]

# **Child Care, Health and Development**

Volume 50, Issue 5 September 2024 <a href="https://onlinelibrary.wiley.com/toc/13652214/current">https://onlinelibrary.wiley.com/toc/13652214/current</a> [Reviewed earlier]

# **Clinical Pharmacology & Therapeutics**

Volume 116, Issue 3 Pages: 479-874 September 2024 <a href="https://ascpt.onlinelibrary.wiley.com/toc/15326535/current">https://ascpt.onlinelibrary.wiley.com/toc/15326535/current</a> <a href="Issue Focus: Getting the Dosage Right">Issue Focus: Getting the Dosage Right</a> <a href="Reviewed earlier">[Reviewed earlier</a>]

# **Clinical Therapeutics**

September 2024 Volume 46 Issue 9 p661-726 <a href="http://www.clinicaltherapeutics.com/current">http://www.clinicaltherapeutics.com/current</a> [Reviewed earlier]

#### **Clinical Trials**

Volume 21 Issue 4, August 2024 https://journals.sagepub.com/toc/ctja/21/4 [Reviewed earlier]

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 21 Sep 2024] [No new digest content identified]

# **Contemporary Clinical Trials**

Volume 144 September 2024 <a href="https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/144/suppl/C">https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/144/suppl/C</a> [Reviewed earlier]

#### The CRISPR Journal

Volume 7, Issue 4 / August 2024 https://www.liebertpub.com/toc/crispr/7/4 [Reviewed earlier]

# **Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023 <a href="https://link.springer.com/journal/40142/volumes-and-issues/11-3">https://link.springer.com/journal/40142/volumes-and-issues/11-3</a> [Reviewed earlier]

# **Current Medical Research and Opinion**

Volume 40, Issue 8 2024 <a href="https://www.tandfonline.com/toc/icmo20/current">https://www.tandfonline.com/toc/icmo20/current</a> [Reviewed earlier]

# **Current Opinion in Infectious Diseases**

October 2024 - Volume 37 - Issue 5 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx [No new digest content identified]

#### **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 21 Sep 2024] [No new digest content identified]

# **Developing World Bioethics**

Volume 24, Issue 3 Pages: 135-261 September 2024 <a href="https://onlinelibrary.wiley.com/toc/14718847/current">https://onlinelibrary.wiley.com/toc/14718847/current</a> [Reviewed earlier]

#### **Development in Practice**

Volume 34, Issue 6, 2024 https://www.tandfonline.com/toc/cdip20/34/6 [Reviewed earlier]

# **Development Policy Review**

Volume 42, Issue 5 September 2024 <a href="https://onlinelibrary.wiley.com/toc/14677679/current">https://onlinelibrary.wiley.com/toc/14677679/current</a> [Reviewed earlier]

#### **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

# [Reviewed earlier]

#### **Disasters**

Volume 48, Issue 4 October 2024 https://onlinelibrary.wiley.com/toc/14677717/2024/48/4 [New issue; No digest content identified]

# **EMBO Reports**

Volume 25 Issue 9 10 September 2024 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

# **Emerging Infectious Diseases**

Volume 30, Number 9—September 2024 <a href="http://wwwnc.cdc.gov/eid/">http://wwwnc.cdc.gov/eid/</a> [Reviewed earlier]

# **Epidemics**

Volume 48 September 2024 <a href="https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C</a> [Reviewed earlier]

# **Epidemiology and Infection**

Volume 152 - 2024

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

#### **Ethics & Human Research**

Volume 46, Issue 4 Pages: 1-51 July—August 2024 <a href="https://onlinelibrary.wiley.com/toc/25782363/current">https://onlinelibrary.wiley.com/toc/25782363/current</a>

**Research with refugee populations Ethical considerations for crowdsourced research** [Reviewed earlier]

#### **Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023 <a href="https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue">https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</a> [Reviewed earlier]

# **Ethics, Medicine and Public Health**

Volume 31 (December 2023) <a href="https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C">https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C</a> [Reviewed earlier]

# The European Journal of Public Health

Volume 34, Issue 4, August 2024 https://academic.oup.com/eurpub/issue/34/4 [Reviewed earlier]

# **Expert Review of Vaccines**

Vol 23 (1) 2023 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

# **Foreign Affairs**

July/August 2024 Volume 103, Number 4 https://www.foreignaffairs.com/issues/2023/103/4 [Reviewed earlier]

# **Forum for Development Studies**

Volume 51, 2024 - Issue 2 <a href="http://www.tandfonline.com/toc/sfds20/current">http://www.tandfonline.com/toc/sfds20/current</a> [Reviewed earlier]

#### **Frontiers in Medicine**

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237 [Accessed 21 Sep 2024]
No new digest content identified]

#### **Genetics in Medicines**

Volume 26, Issue 9 September 2024 <a href="https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/9">https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/9</a> [Reviewed earlier]

#### **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles
[Accessed 21 Sep 2024]
[No new digest content identified]

#### **Global Health Action**

Volume 17, Issue 1 (2024) <a href="https://www.tandfonline.com/toc/zgha20/current?nav=tocList">https://www.tandfonline.com/toc/zgha20/current?nav=tocList</a> [Reviewed earlier]

# **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 4 August 27, 2024 <a href="http://www.ghspjournal.org/content/current">http://www.ghspjournal.org/content/current</a> [Reviewed earlier]

# Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date desc

[Accessed 21 Sep 2024]

[No new digest content identified]

#### **Global Public Health**

Volume 19, Issue 1 (2024) <a href="http://www.tandfonline.com/toc/rgph20/current">http://www.tandfonline.com/toc/rgph20/current</a> [Reviewed earlier]

#### **Globalization and Health**

http://www.globalizationandhealth.com/

[Accessed 21 Sep 2024]

Assessing the health status of migrants upon arrival in Europe: a systematic review of the adverse impact of migration journeys

Numerous studies have explored the impact of pre- and post-migration factors on the overall health of migrant populations. The objective of this study is to enhance our understanding of additional determinants...

Authors: Cristina Canova, Lucia Dansero, Cinzia Destefanis, Clara Benna and Isabella Rosato

Citation: Globalization and Health 2024 20:69

Content type: Review Published on: 27 September 2024

#### **Health and Human Rights**

Volume 26, Issue 1, June 2024 https://www.hhrjournal.org/volume-26-issue-1-june-2024/ SPECIAL SECTION — COMMEMORATING 30 YEARS [Reviewed earlier]

# **Health Economics, Policy and Law**

Volume 19 - Issue 2 - April 2024 <a href="https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue">https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue</a> [Reviewed earlier]

#### **Health Policy and Planning**

Volume 39, Issue 8, October 2024 https://academic.oup.com/heapol/issue/39/8 [Reviewed earlier]

# **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 21 Sep 2024] [No new digest content identified]

# **Human Gene Therapy**

Volume 35, Issue 17-18 / September 2024 <a href="https://www.liebertpub.com/toc/hum/35/17-18">https://www.liebertpub.com/toc/hum/35/17-18</a> [Reviewed earlier]

#### **Humanitarian Practice Network**

https://odihpn.org/ Featured Publications [No new digest content identified]

# **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024 https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList Selected Content [Reviewed earlier]

# **Immunity**

Sep 10, 2024 Volume 57 Issue 9 p1995-2250 <a href="https://www.cell.com/immunity/current">https://www.cell.com/immunity/current</a> [Reviewed earlier]

# **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 21 Sep 2024] [No new digest content identified]

#### **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 21 Sep 2024] [No new digest content identified]

#### **International Health**

Volume 16, Issue 5, September 2024 <a href="https://academic.oup.com/inthealth/issue/16/5">https://academic.oup.com/inthealth/issue/16/5</a> [Reviewed earlier]

#### **International Human Rights Law Review**

Volume 13 (2024): Issue 1 (Jun 2024): <a href="https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml">https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml</a>

\*\*Special Issue on Inter-State Communications

\*Table of Contents

[Reviewed earlier]

# **International Journal of Community Medicine and Public Health**

Vol. 11 No. 9 (2024): September 2024

https://www.ijcmph.com/index.php/ijcmph/issue/view/116

[Reviewed earlier]

# **International Journal of Epidemiology**

Volume 53, Issue 4, August 2024 https://academic.oup.com/ije/issue/53/4 [Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 17 Issue 3 2024 <a href="https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/3">https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/3</a> Table of contents [Reviewed earlier]

#### **JAMA**

September 24, 2024, Vol 332, No. 12, Pages 945-1030 <a href="https://jamanetwork.com/journals/jama/currentissue">https://jamanetwork.com/journals/jama/currentissue</a> [New issue; No digest content identified]

#### **JAMA Health Forum**

September 2024, Vol 5, No. 9 <a href="https://jamanetwork.com/journals/jama-health-forum/issue">https://jamanetwork.com/journals/jama-health-forum/issue</a> [Reviewed earlier]

#### **JAMA Pediatrics**

September 2024, Vol 178, No. 9, Pages 847-956 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

#### **JBI Evidence Synthesis**

August 2024 - Volume 22 - Issue 8 <a href="https://journals.lww.com/jbisrir/Pages/currenttoc.aspx">https://journals.lww.com/jbisrir/Pages/currenttoc.aspx</a> [Reviewed earlier]

#### **Journal of Adolescent Health**

September 2024 Volume 75 Issue 3 p375-52 <a href="https://www.jahonline.org/current">https://www.jahonline.org/current</a> [Reviewed earlier]

# **Journal of Artificial Intelligence Research**

Vol. 80 (2024) https://www.jair.org/index.php/jair Contents [Reviewed earlier]

# **Journal of Community Health**

Volume 49, Issue 5 October 2024 https://link.springer.com/journal/10900/volumes-and-issues/49-5 [Reviewed earlier]

# **Journal of Current Medical Research and Opinion**

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024, Page 1988-1996

https://www.cmro.in/index.php/jcmro/issue/view/75

[Reviewed earlier]

# **Journal of Development Economics**

Volume 170 September 2024 <a href="https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C">https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C</a> [Reviewed earlier]

# **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 3, July 2024 <a href="http://journals.sagepub.com/toc/jre/current">http://journals.sagepub.com/toc/jre/current</a> **Special Issues in Research and IRB/REC Functioning, Including the use of AI**[Reviewed earlier]

# **Journal of Epidemiology & Community Health**

August 2024 - Volume 78 - 8 https://jech.bmj.com/content/78/8 [Reviewed earlier]

#### **Journal of Evidence-Based Medicine**

Volume 17, Issue 2 Pages: 237-467 June 2024 <a href="https://onlinelibrary.wiley.com/toc/17565391/current">https://onlinelibrary.wiley.com/toc/17565391/current</a> [Reviewed earlier]

#### **Journal of Global Ethics**

Volume 20, Issue 1 (2024) <a href="http://www.tandfonline.com/toc/rjge20/current">http://www.tandfonline.com/toc/rjge20/current</a> [Reviewed earlier]

# Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 3, August 2024 <a href="https://muse.jhu.edu/issue/52935">https://muse.jhu.edu/issue/52935</a> *Table of Contents*[Reviewed earlier]

# **Journal of Immigrant and Minority Health**

Volume 26, Issue 4 August 2024 https://link.springer.com/journal/10903/volumes-and-issues/26-4 [Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 3 https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

# **Journal of International Development**

Volume 36, Issue 6 Pages: 3-2669 August 2024 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

#### **Journal of Medical Ethics**

September 2024 - Volume 50 - 9 http://jme.bmj.com/content/current [Reviewed earlier]

#### **Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 1 (2024) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

#### The Journal of Pediatrics

Volume 272 September 2024 <a href="https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/272/suppl/C">https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/272/suppl/C</a> [New issue; No digest content identified]

# **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1 <a href="https://www.tandfonline.com/toc/jppp20/17/1">https://www.tandfonline.com/toc/jppp20/17/1</a> [Reviewed earlier]

#### **Journal of Public Health Management & Practice**

September/October 2024 - Volume 30 - Issue 5 https://journals.lww.com/jphmp/pages/currenttoc.aspx

# [Reviewed earlier]

# **Journal of Public Health Policy**

Volume 45, issue 3, September 2024 https://link.springer.com/journal/41271/volumes-and-issues/45-3 [Reviewed earlier]

# **Journal of the Royal Society – Interface**

September 2024 Volume 21 Issue 218 <a href="https://royalsocietypublishing.org/toc/rsif/current">https://royalsocietypublishing.org/toc/rsif/current</a> [Reviewed earlier]

### **Journal of Travel Medicine**

Volume 31, Issue 6, August 2024 <a href="https://academic.oup.com/jtm/issue">https://academic.oup.com/jtm/issue</a> [Reviewed earlier]

# **Journal of Virology**

Volume 98 • Number 6 • June 2024 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [Reviewed earlier]

#### The Lancet

Sep 28, 2024 volume 404 Number 10459 p1171-1278 https://www.thelancet.com/journals/lancet/issue/current Comment

Global burden of antimicrobial resistance and forecasts to 2050

Samuel Kariuki

#### **Articles**

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

GBD 2021 Antimicrobial Resistance Collaborators

#### The Lancet Child & Adolescent Health

Sep 2024 Volume 8 Number 9 p611-706, e7-e11 <a href="https://www.thelancet.com/journals/lanchi/issue/current">https://www.thelancet.com/journals/lanchi/issue/current</a> [Reviewed earlier]

# **Lancet Digital Health**

Sep 2024 Volume 6 Number 9 e601-e672 <a href="https://www.thelancet.com/journals/landig/issue/current">https://www.thelancet.com/journals/landig/issue/current</a> [Reviewed earlier]

#### **Lancet Global Health**

Sep 2024 Volume 12 Number 9 e1370-e1559 <a href="https://www.thelancet.com/journals/langlo/issue/current">https://www.thelancet.com/journals/langlo/issue/current</a> [Reviewed earlier]

#### **Lancet Infectious Diseases**

Sep 2024 Volume 24 Number 9 p935-1058, e540-e601 <a href="https://www.thelancet.com/journals/laninf/issue/current">https://www.thelancet.com/journals/laninf/issue/current</a> [Reviewed earlier]

#### **Lancet Public Health**

Sep 2024 Volume 9 Number 9 e635-e708 <a href="https://www.thelancet.com/journals/lanpub/issue/current">https://www.thelancet.com/journals/lanpub/issue/current</a> [Reviewed earlier]

# **Lancet Respiratory Medicine**

Sep 2024 Volume 12 Number 9 p655-742, e52-e56 <a href="https://www.thelancet.com/journals/lanres/issue/current">https://www.thelancet.com/journals/lanres/issue/current</a> [Reviewed earlier]

# **Maternal and Child Health Journal**

Volume 28, Issue 9 September 2024 https://link.springer.com/journal/10995/volumes-and-issues/28-9 [New issue; No digest content identified]

# **Medical Decision Making (MDM)**

Volume 44 Issue 6, August 2024 <a href="http://mdm.sagepub.com/content/current">http://mdm.sagepub.com/content/current</a> [Reviewed earlier]

# The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 102, Issue 3 Pages: 517-821 September 2024 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [Reviewed earlier]

#### **Molecular Therapy**

Sep 04, 2024 Volume 32 Issue 9 p2801-3194 <a href="https://www.cell.com/molecular-therapy/current">https://www.cell.com/molecular-therapy/current</a> [Reviewed earlier]

#### **Nature**

Volume 633 Issue 8031, 26 September 2024 <a href="https://www.nature.com/nature/volumes/633/issues/8031">https://www.nature.com/nature/volumes/633/issues/8031</a>

[New issue; No digest content identified]

# **Nature Biotechnology**

Volume 42 Issue 9, September 2024 https://www.nature.com/nbt/volumes/42/issues/9 [Reviewed earlier]

#### **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed21 Sep 2024) [No new digest content identified]

#### **Nature Genetics**

Volume 56 Issue 9, September 2024 <a href="https://www.nature.com/ng/volumes/56/issues/9">https://www.nature.com/ng/volumes/56/issues/9</a> [Reviewed earlier]

#### **Nature Human Behaviour**

Volume 8 Issue 9, September 2024 https://www.nature.com/nathumbehav/volumes/8/issues/9 Comment 09 Sept 2024

### What we should learn from pandemic publishing

Authors of COVID-19 papers produced during the pandemic were overwhelmingly not subject matter experts. Such a massive inflow of scholars from different expertise areas is both an asset and a potential problem. Domain-informed scientific collaboration is the key to preparing for future crises. Satyaki Sikdar, Sara Venturini, Maimuna S. Majumde

Perspective 20 Sept 2024

#### How large language models can reshape collective intelligence

Collective intelligence is the basis for group success and is frequently supported by information technology. Burton et al. argue that large language models are transforming information access and transmission, presenting both opportunities and challenges for collective intelligence.

Jason W. Burton, Ezequiel Lopez-Lopez, Ralph Hertwig

Article 01 Aug 2024

# A systematic review and meta-analysis of strategies to promote vaccination uptake

Liu et al. present a systematic review and meta-analysis of 88 randomized controlled trials testing the effectiveness of seven intervention strategies for increasing vaccination uptake. Sicong Liu, Marta R. Durantini, Dolores Albarracin

#### **Nature Medicine**

Volume 30 Issue 9, September 2024 <a href="https://www.nature.com/nm/volumes/30/issues/9">https://www.nature.com/nm/volumes/30/issues/9</a> [Reviewed earlier]

# **Nature Reviews Drug Discovery**

Volume 23 Issue 9, September 2024 <a href="https://www.nature.com/nrd/volumes/23/issues/9">https://www.nature.com/nrd/volumes/23/issues/9</a> [Reviewed earlier]

#### **Nature Reviews Genetics**

Volume 25 Issue 9, September 2024 https://www.nature.com/nrg/volumes/25/issues/9 [Reviewed earlier]

# **Nature Reviews Immunology**

Volume 24 Issue 9, September 2024 <a href="https://www.nature.com/nri/volumes/24/issues/9">https://www.nature.com/nri/volumes/24/issues/9</a> [Reviewed earlier]

# **New England Journal of Medicine**

Volume 391 No. 12 September 26, 2024 <a href="https://www.nejm.org/toc/nejm/medical-journal">https://www.nejm.org/toc/nejm/medical-journal</a> <a href="https://edi.org/toc/nejm/medical-journal">Editorials</a>

# <u>Creeping toward Effective Antiviral Agents for RSV Infection</u>

E.E. Walsh

#### **NEJM Evidence**

Volume 3 No. 9 September 2024 <a href="https://evidence.nejm.org/toc/evid/current">https://evidence.nejm.org/toc/evid/current</a>
<a href="https://evidence.nejm.org/toc/evid/current">NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.</a>
<a href="https://evidence.nejm.org/toc/evid/current">[Reviewed earlier]</a>

#### njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 21 Sep 2024] [Reviewed earlier]

#### **Pediatrics**

Volume 154, Issue 3 September 2024 <a href="https://publications.aap.org/pediatrics/issue/154/3">https://publications.aap.org/pediatrics/issue/154/3</a> [Reviewed earlier]

#### **PharmacoEconomics**

Volume 42, Issue 9 September 2024 <a href="https://link.springer.com/journal/40273/volumes-and-issues/42-9">https://link.springer.com/journal/40273/volumes-and-issues/42-9</a> [Reviewed earlier]

# **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 21 Sep 2024) [No new digest content identified]

#### **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 21 Sep 2024) [No new digest content identified]

#### **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\_NEWEST\_FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 21 Sep 2024)

# <u>Adverse events following COVID-19 vaccination: A comprehensive analysis of spontaneous</u> reporting data in Ghana

Amma Frempomaa Asare, George Tsey Sabblah, Richard Osei Buabeng, Yakubu Alhassan, Abena Asamoa-Amoakohene, Kwame Amponsa-Achiano, Naziru Tanko Mohammed, Delese Mimi Darko, Harriet Affran Bonful

Research Article | published 27 Sep 2024 PLOS Global Public Health <a href="https://doi.org/10.1371/journal.pgph.0003770">https://doi.org/10.1371/journal.pgph.0003770</a>

# **Ebola: Ten years later—Lessons learned and future pandemic preparedness**

Krutika Kuppalli

Opinion | published 26 Sep 2024 PLOS Global Public Health <a href="https://doi.org/10.1371/journal.pgph.0003662">https://doi.org/10.1371/journal.pgph.0003662</a>

# Mentorship in health research institutions in Africa: A systematic review of approaches, benefits, successes, gaps and challenges

Maurine Ng'oda, Peter Muriuki Gatheru, Oyetunde Oyeyemi, Phylis Busienei, Caroline H. Karugu, Sharon Mugo, Lilian Okoth, Margaret Nampijja, Sylvia Kiwuwa-Muyingo, Yohannes Dibaba Wado, Patricia Kitsao-Wekulo, Gershim Asiki, Evelyn Gitau

Research Article | published 23 Sep 2024 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0003314

#### **PLoS Medicine**

https://journals.plos.org/plosmedicine/ (Accessed 21 Sep 2024) [No new digest content identified]

# **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/ (Accessed 21 Sep 2024) [No new digest content identified]

#### **PLoS One**

http://www.plosone.org/ [Accessed 21 Sep 2024]

# <u>Upstream factors impacting COVID-19 vaccination rates across Africa: A systematic review</u> protocol

Obidimma Ezezika, Tiana Stephanie Kotsaftis, Alanna Marson Study Protocol | published 25 Sep 2024 PLOS ONE <a href="https://doi.org/10.1371/journal.pone.0310884">https://doi.org/10.1371/journal.pone.0310884</a>

# **PLoS Pathogens**

http://journals.plos.org/plospathoge ns/ [Accessed 21 Sep 2024] [No new digest content identified]

# PNAS - Proceedings of the National Academy of Sciences of the United States

September 17, 2024 vol. 121 no. 38 <a href="https://www.pnas.org/toc/pnas/121/38">https://www.pnas.org/toc/pnas/121/38</a> [New issue; No digest content identified]

#### **PNAS Nexus**

Volume 3, Issue 8, August 2024 https://academic.oup.com/pnasnexus/issue/3/8 [Reviewed earlier]

# **Prehospital & Disaster Medicine**

Volume 39 - Issue 2 - April 2024 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

#### **Preventive Medicine**

Volume 187 October 2024 <a href="https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C">https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C</a> [New issue; No digest content identified]

# **Proceedings of the Royal Society B**

September 2024 Volume 291 Issue 2030 <a href="https://royalsocietypublishing.org/toc/rspb/current">https://royalsocietypublishing.org/toc/rspb/current</a> [Reviewed earlier]

#### **Public Health**

Volume 235 Pages 1-218 (October 2024) <a href="https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C">https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C</a> [Reviewed earlier]

#### **Public Health Ethics**

Volume 17, Issue 1-2, April/July 2024 <a href="http://phe.oxfordjournals.org/content/current">http://phe.oxfordjournals.org/content/current</a>

# [Reviewed earlier]

# **Public Health Genomics**

2024, Vol. 27, No. 1 https://karger.com/phg/issue/27/1 [Reviewed earlier]

# **Public Health Reports**

Volume 139 Issue 5, September/October 2024 <a href="https://journals.sagepub.com/toc/phrg/139/5">https://journals.sagepub.com/toc/phrg/139/5</a> [Reviewed earlier]

# **Qualitative Health Research**

Volume 34 Issue 10, August 2024 <a href="https://journals.sagepub.com/toc/QHR/current">https://journals.sagepub.com/toc/QHR/current</a> [Reviewed earlier]

# **Research Ethics**

Volume 20 Issue 3, July 2024 <a href="http://journals.sagepub.com/toc/reab/current">http://journals.sagepub.com/toc/reab/current</a> [Reviewed earlier]

#### **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 21 Sep 2024] [No new digest content identified]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles [No new digest content identified]

#### **Risk Analysis**

Volume 44, Issue 9 Pages: 1977-2311 September 2024 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a> [Reviewed earlier]

# **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 21 Sep 2024] [Reviewed earlier]

#### Science

Volume 385| Issue 6716| 27 Sep 2024 https://www.science.org/toc/science/current [New issue; No digest content identified]

# **Science and Engineering Ethics**

Volume 30, Issue 5 October 2024 https://link.springer.com/journal/11948/volumes -and-issues/30-5 [Reviewed earlier]

### **Science Translational Medicine**

Volume 16| Issue 766| 25 Sep 2024 https://www.science.org/toc/stm/current [New issue; No digest content identified]

### **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 21 Sep 2024] [No new digest content identified]

#### **Social Science & Medicine**

Volume 358 October 2024 <a href="https://www.sciencedirect.com/journal/social-science-and-medicine/vol/358/suppl/C">https://www.sciencedirect.com/journal/social-science-and-medicine/vol/358/suppl/C</a> [Reviewed earlier]

# **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 21 Sep 2024] [No new digest content identified]

#### **Theoretical Medicine and Bioethics**

Volume 45, Issue 5 October 2024 https://link.springer.com/journal/11017/volumes-and-issues/45-5 [Reviewed earlier]

#### **Travel Medicine and Infectious Diseases**

Volume 61 September–October 2024 <a href="https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C">https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C</a> [Reviewed earlier]

# **Tropical Medicine & International Health**

Volume 29, Issue 9 Pages: i-iv, 757-847 September 2024 <a href="https://onlinelibrary.wiley.com/toc/13653156/current">https://onlinelibrary.wiley.com/toc/13653156/current</a> [Reviewed earlier]

#### **Vaccine**

Volume 42, Issue 25 14 November 2024

https://www.sciencedirect.com/journal/vaccine/vol/42/issue/25

Short communication Open access

Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer

Peter M. Dull, Sharon L. Achilles, Rafi Ahmed, Ruanne V. Barnabas, ... Aimée R. Kreimer Article 126100

Review article Open access

<u>Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity:</u>
<u>A systematic review and meta-analysis</u>

Lauren Pischel, Brett A. Martini, Natalle Yu, David Cacesse, ... Saad B. Omer Article 126053

Review article Open access

<u>Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and *meta*-analysis</u>

Aysegul Humeyra Kafadar, Serena Sabatini, Katy A. Jones, Tom Dening Article 126092

Research article Open access

<u>Preferences of US adolescents and parents for vaccination against invasive meningococcal disease</u>

Katharina Schley,

Research article Open access

Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction

Jennifer R. Verani, Daniel Omondi, Arthur Odoyo, Herine Odiembo, ... Godfrey Bigogo

**Article 126120** 

Research article Abstract only

Americans' willingness to give to global immunization programs: Political heterogeneity in preferences for program management and response to priming communications

William F. Vásquez, Jennifer M. Trudeau

Article 126126

Articles from the Special Issue on Canadian COVID-19 Experiences; Edited by Dr Helena Maltezou Research article Abstract only

Pediatric HPV vaccination: Provider recommendations matter among hesitant parents

Don E. Willis, Ramey Moore, James P. Selig, Neveen Shafeek Amin, ... Pearl A. McElfish Article 126166

#### **Vaccines**

https://www.mdpi.com/journal/vaccines

[Accessed 21 Sep 2024]

Open Access Opinion

Position Statement about Gender-Neutral HPV Vaccination in Korea

by Kyung-Jin Min, Yung-Taek Ouh, Sangrak Bae, Yong-Bae Ji, Jae-Kwan Lee, Jae-Weon Kim, Kwang-Jae Cho and Dong-Hun Im

Vaccines 2024, 12(10), 1110; <a href="https://doi.org/10.3390/vaccines12101110">https://doi.org/10.3390/vaccines12101110</a> - 27 Sep 2024

Abstract

Given the rising incidence of human papillomavirus (HPV)-related diseases, including cervical, penile, and oropharyngeal cancers, particularly among men, the implementation of comprehensive HPV vaccination strategies is necessary in South Korea. This position statement advocates the introduction of gender-neutral vaccination (GNV) in the country.

# Open Access Article

<u>COVID-19 Vaccination and Vaccine Hesitancy in the Gaza Strip from a Cross-Sectional Survey in 2023: Prevalence, Risk Factors, and Associations with Health System Interventions</u>

by Jennifer Majer, Jehad H. Elhissi, Nabil Mousa, Jill John-Kall and Natalya Kostandova Vaccines 2024, 12(10), 1098; <a href="https://doi.org/10.3390/vaccines12101098">https://doi.org/10.3390/vaccines12101098</a> - 26 Sep 2024 Abstract

Background: Preventing COVID-19 in Gaza is crucial due to the devastation of advanced health services infrastructure by war. Despite the high protection offered by COVID-19 vaccines against severe disease, a 2021 survey in Gaza found only half of the population was vaccinated, and

#### Open Access Review

# <u>Progress towards Measles and Rubella Elimination in the South-East Asia Region—2013—</u> 2023

by Sudhir Khanal, Vinod Bura, Lucky Sangal, Raman Sethi, Deepak Dhongde and Sunil Kumar Bahl Vaccines 2024, 12(10), 1094; <a href="https://doi.org/10.3390/vaccines12101094">https://doi.org/10.3390/vaccines12101094</a> - 25 Sep 2024

Abstract

The South-East Asia (SEA) Region of the World Health Organization (WHO), through a Regional Committee resolution in 2013, adopted the goal of "measles elimination and rubella control by 2020". The goal was revised in 2019 to "measles and rubella elimination by 2023". Countries [.

### **Value in Health**

September 2024 Volume 27 Issue 9 p1175-1310 <a href="https://www.valueinhealthjournal.com/current">https://www.valueinhealthjournal.com/current</a> [Reviewed earlier]

# **World Development**

Volume 181 September 2024 <a href="https://www.sciencedirect.com/journal/world-development/vol/181/suppl/C">https://www.sciencedirect.com/journal/world-development/vol/181/suppl/C</a> [New issue; No digest content identified]

::::::

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: <u>Pre-Print Servers</u>

::::::

::::::

#### **Pre-Print Servers**

#### arxiv

https://arxiv.org/

[Accessed 21 Sep 2024]

[Filter: Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology;

General Economics]

[No new digest content identified]

# **Gates Open Research**

https://gatesopenresearch.org/browse/articles

[Accessed 21 Sep 2024]

Study Protocol metrics AWAITING PEER REVIEW

<u>Effects of a single oral dose of azithromycin in laboring women on antimicrobial resistance</u>
(AMR) and the microbiome: a protocol for the Antimicrobial Resistance Sub-Study of the A-PLUS trial

[version 1; peer review: awaiting peer review]

Jean H. Kim, Denise Babineau, Janet L. Moore, Akila Subramaniam, Alan Tita, Elwyn Chomba, Musaku Mwenchanya, Adrien Lokangaka, Antoinette Tshefu, Archana Patel, Prabir Das, Shivaprasad S. Goudar, Shiyam Sunder Tikmani, Imran Ahmed, Sarah Saleem, Fabian Esamai, Manolo Mazariegos, Sk Masum Billah, Rashidul Haque, Robert L. Goldenberg, Melissa Bauserman, Sherri Bucher, Nancy F. Krebs, Richard J. Derman, William A. Petri Jr, Marion Koso-Thomas, Jennifer J. Hemingway-Foday, Anna Aceituno, Elizabeth M. McClure, Doyle V. Ward, Sixto Leal, Waldemar A. Carlo, Patricia L. Hibberd, A-PLUS AMR Study Group

Peer Reviewers Invited

- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Foundation for the National Institutes of Health

PUBLISHED 24 Sep 2024

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 21 Sep 2024] [Filter: All articles]

<u>Current infectious disease research practices with forcibly displaced people in the top ten</u> low- and middle-income host countries: A Systematic Review

Neila Gross, Maia C Tarnas, Rashmina J Sayeeda, Carly Ching, David Flynn, Muhammad H Zaman medRxiv 2024.09.24.24314319; doi: https://doi.org/10.1101/2024.09.24.24314319 Abstract

Infectious disease research is essential for disease prevention and management within refugee camps and informal settlements. We aim to assess the state of infectious disease research with displaced communities in the top ten refugee-hosting low- and middle-income countries. We searched three journal databases for primary research that explicitly included refugees or was conducted in a refugee camp, informal settlement, or displaced people-serving hospital and focused directly on an infectious disease following PRISMA guidelines. Forty studies (out of 1,179) met the inclusion criteria. Common research challenges included population mobility, limited external validity, and low recruitment. No studies included the community in the initial study conception or investigated the research impact on the community. Community involvement was often through community health workers (45%). Of the

18 studies that studied a resource-based intervention, 20% explicitly noted that the intervention was unsustainable. Such context-specific considerations are vital in research with displaced communities.

# Human papillomavirus vaccination at the national level in Tunisia: a cost-effectiveness analysis using a comparative modeling study.

Oumaima Laraj, Beya Benzina, Ahlem Gzara, Amira Kebir, Kaja Abbas, Slimane Ben Miled medRxiv 2024.09.17.24313756; doi: https://doi.org/10.1101/2024.09.17.24313756 Revision

# From Biobanking to Personalized Medicine: the journey of the Estonian Biobank

Lili Milani, Maris Alver, Sven Laur, Sulev Reisberg, Toomas Haller, Oliver Aasmets, Erik Abner, Helene Alavere, Annely Allik, Tarmo Annilo, Krista Fischer, Georgi Hudjashov, Maarja Jõeloo, Mart Kals, Liis Karo-Astover, Silva Kasela, Anastassia Kolde, Kristi Krebs, Kertu Liis Krigul, Jaanika Kronberg, Karoliina Kruusmaa, Viktorija Kukuškina, Kadri Kõiv, Kelli Lehto, Liis Leitsalu, Sirje Lind, Laura Birgit Luitva, Kristi Läll, Kreete Lüll, Kristjan Metsalu, Mait Metspalu, René Mõttus, Mari Nelis, Tiit Nikopensius, Miriam Nurm, Margit Nõukas, Marek Oja, Elin Org, Marili Palover, Priit Palta, Vasili Pankratov, Kateryna Pantiukh, Natalia Pervjakova, Natàlia Pujol-Gualdo, Anu Reigo, Ene Reimann, Steven Smit, Diana Sokurova, Nele Taba, Harry-Anton Talvik, Maris Teder-Laving, Neeme Tõnisson, Mariliis Vaht, Uku Vainik, Urmo Võsa, Tõnu Esko, Raivo Kolde, Reedik Mägi, Jaak Vilo, Triin Laisk, Andres Metspalu medRxiv 2024.09.22.24313964; doi: https://doi.org/10.1101/2024.09.22.24313964

Large biobanks have set a new standard for research and innovation in human genomics and implementation of personalised medicine. The Estonian Biobank was founded a quarter of a century ago, and its biological specimens, clinical, health, omics, and lifestyle data have been included in over 800 publications to date. What makes the biobank unique internationally is its translational focus, with active efforts to conduct clinical studies based on genetic findings, and to explore the effects of return of results on participants. In this review we provide an overview of the Estonian Biobank, highlight its strengths for studying the effects of genetic variation and quantitative phenotypes on health-related traits, development of methods and frameworks for bringing genomics into the clinic, and its role as a driving force for implementing personalized medicine on a national level and beyond.

# A decade of shifting cholera burden in Africa and its implications for control: a statistical mapping analysis

Javier Perez-Saez, Qulu Zheng, Joshua Kaminsky, Kaiyue Zou, Maya N. Demby, Christina Alam, Daniel Landau, Rachel DePencier, Jose Paulo M. Langa, Roma Chilengi, Placide Welo Okitayemba, Godfrey Bwire, Linda Esso, Armelle Viviane Ngomba, Nicole Fouda Mbarga, Emmanuel Wandera Okunga, Sebastian Yennan, Fred Kapaya, Stephen Ogirima Ohize, Adive Joseph Seriki, Sonia T. Hegde, Mustafa Sikder, Justin Lessler, Abhirup Datta, Andrew S. Azman, Elizabeth C. Lee medRxiv 2024.09.23.24314072; doi: https://doi.org/10.1101/2024.09.23.24314072

# The potential global impact and cost-effectiveness of next-generation influenza vaccines: a modelling analysis

Lucy Goodfellow, Simon R Procter, Mihaly Koltai, Naomi R Waterlow, Johnny A N Filipe, Carlos K H Wong, Edwin van Leeuwen, WHO Technical Advisory Group for the Full Value of Influenza Vaccines Assessment, Rosalind M Eggo, Mark Jit

medRxiv 2024.09.19.24313950; doi: https://doi.org/10.1101/2024.09.19.24313950

#### **OSF Pre-prints**

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre[No new digest content identified]

### **Wellcome Open Research**

https://wellcomeopenresearch.org/browse/articles

[Accessed 28 Sep 2024]

Selected Research

Data Note Open Access

The Ebola Data Platform: A prospective, standardised, clinical dataset collected during the 2013-2016 West African Ebola outbreak

[version 1; peer review: awaiting peer review]

Laura Merson, et al.

**Abstract** 

The Ebola Data Platform (EDP) was developed to strengthen knowledge and capacity across health, research, and humanitarian communities to reduce the impact of Ebola through responsible data use. This collaborative initiative was established by West African governments, NGOs, academic organisations, and intra-governmental health organisations directly involved in the 2013–2016 West African Ebola outbreak. The platform was established to provide a centralised, standardised dataset of individual patient data collected during the outbreak for the purpose of research to improve Ebola treatment and control, and includes over 13,600 patient records of individuals infected and treated from 22 different Ebola treatment centres across Guinea, Sierra Leone, Liberia, and Nigeria. Patient data are available from treatment centre triage and admission, inpatient clinical observations, and outcomes, with outpatient follow-up available for some datasets. Data include signs and symptoms, pre-existing comorbidities, vital signs, laboratory testing, treatments, complications, dates of admission and discharge, mortality, viral strains, and other data. This publication describes characteristics of the EDP dataset, its architecture, methods for data access and tools for utilising the dataset.

\* \* \*

# <u>Think Tanks</u>

**Brookings** [to 21 Sep 2024] http://www.brookings.edu/ Research No new digest content identified.

## **Center for Global Development** [to 28 Sep 2024]

https://www.cgd ev.org/ All Research REPORTS

# <u>Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in</u> Humans

Anthony McDonnell et al.

September 25, 2024

Antimicrobial resistance (AMR) poses a significant threat to global health and economic stability. This report integrates human health burden projections with economic models to provide a comprehensive analysis of the impact of AMR on global economies and health systems.

**Chatham House** [to 21 Sep 2024] <a href="https://www.chathamhouse.org/">https://www.chathamhouse.org/</a>
Selected Analysis, Comment, Events

No new digest content identified.

# **Council on Foreign Relations** [to 21 Sep 2024]

https://www.cfr.org/media/news-releases
New Releases [Selected]
No new digest content identified.

CSIS [to 21 Sep 2024]
https://www.csis.org/
Reports [Selected]
No new digest content identified.

**Kaiser Family Foundation** [to 21 Sep 2024] https://www.kff.org/search/?post\_type=press-release Newsroom No new digest content identified.

# McKinsey Global Institute [to 21 Sep 2024]

https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

# **ODI [Overseas Development Institute]** [to 21 Sep 2024]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

#### **Pew Research Center** [to 21 Sep 2024]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

**Rand** [to 21 Sep 2024]

https://www.rand.org/pubs.html Published Research [Selected]

# <u>Perceived Versus Actual Costs of HIV Pre-Exposure Prophylaxis Among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States</u>

This study uses a survey to examine the differences between perceived and actual costs among men who have and have not used PrEP for HIV prevention. Sep 27, 2024

# Always 2020: A Cost-Benefit Analysis of the DoD's COVID-19 Vaccine Mandate

This retrospective, ex ante analysis examines the cost-benefit implications of the COVID-19 vaccine mandate implemented by the DoD in August 2021, following the full FDA licensing of the Pfizer-BioNTech Comirnaty vaccine.

Urban Institute [to 21 Sep 2024] https://www.urban.org/publications New Research Publications - Selected

#### World Economic Forum [to 21 Sep 2024]

https://agenda.weforum.org/press/

Media [Selected]

<u>Sustainable Development Impact Meetings 2024 to Drive Transformative Action on the SDGS</u>

News 18 Sep 2024

- :: The World Economic Forum's Sustainable Development Impact Meetings 2024 are taking place on 23 to 27 September in New York.
- :: The meetings will focus on reinvigorating multistakeholder momentum on the Sustainable Development Goals through innovative cross-sector partnerships.
- :: More than 1,000 global leaders will come together to exchange perspectives and accelerate the concerted collaboration needed to advance progress on the UN objectives by 2030.
- :: Follow the Sustainable Development Impact Meetings 2024 here

::::::

# **Public Consultations/Call for Inputs/Call for Papers**

<u>Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.</u>

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Public consultation dates [announced to date]:

ANVISA, Brazil - Deadline for comments by 24 August 2024 FDA, United States - Deadline for comments by 3 September 2024 MFDS, Republic of Korea - Deadline for comments by 15 July 2024 MHLW/PMDA, Japan - Deadline for comments by 28 July 2024 NMPA, China - Deadline for comments by 12 October 2024 TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

......

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.